摘要
子宫内膜异位症(Ems)高发于育龄期妇女,通常采用保守性手术和(或)药物治疗。传统药物通过抑制卵巢雌激素分泌来抑制内膜病灶的生长,复发率高,不良反应较大。目前,促性腺激素释放激素激动剂已经投入临床使用。另外的一些新型制剂(如促性腺激素释放激素拮抗剂、芳香化酶抑制剂、选择性雌激素受体调节剂、选择性黄体酮受体调节剂等)正处于研发阶段,其治疗EMS的机制、疗效、安全性得到了广泛的研究,且有望成为治疗EMS的新途径,来弥补现有治疗方法的不足。
Endometriosis （Ems）mainly occur in women of reproductive age, who usually receive conservative surgery and（or） drugs treatment. The traditional drugs for EMS restrain the growth of endometrial lesions primarily by inhibiting ovarian hormone secretion,however,with high recurrence rate and side effects. At presen, GnRHa has been widely used in clinic ; other new agents such as GnRHA, AI, SERM, SPRM, etc. are still in the development stage, and their mechanisms, therapeutic effect and safety for treating EMS have been extensively studied. These new agents are likely to become the new ways to treat EMS,making up for the deficiency of the existing treatment methods.
出处
《医学综述》
2012年第15期2452-2455,共4页
Medical Recapitulate
